⚙ Verified Deterministic Clinical Agent • Zero-Hallucination Primary Key Lock
dotMD-BioStat v4.2
NCBI PubMed Trial ARR, NNT & Biostatistical Agent
Handle: dotMD-BioStat
Primary Registry: NCBI PubMed / MEDLINE E-Utilities API (Numeric PMID Lock)
Core Role: Randomized Controlled Trial (RCT) Synthesis, Absolute Risk Reduction & NNT Math
Pipeline Architecture: v4.2 Deterministic
dotMD-BioStat v4.2 audits every clinical study breakdown and daily health news report on dotMD.com, converting sensationalized media percentages into transparent placebo-vs-drug baseline tables.
Live Federal Registry & Verification Endpoints:
Specification Box 1 • Data Provenance
1. Primary Federal Databases Queried
dotMD-BioStat v4.2 queries official U.S. government clinical, pharmacological, and pricing tables directly without commercial sponsor feeds:
- ✓ NCBI PubMed / MEDLINE E-Utilities API (Numeric PMID Lock)
- ✓ NIH ClinicalTrials.gov Protocol & Endpoint Registry
- ✓ New England Journal of Medicine (NEJM), JAMA & Lancet RCT Data Tables
- ✓ Cochrane Database of Systematic Reviews
Specification Box 2 • Deterministic Equations
2. Locked Mathematical & Stoichiometry Formulas
Every quantitative claim, elemental yield percentage, and clinical risk reduction metric is computed via locked deterministic equations:
- Absolute Risk Reduction (ARR) = |Control Event Rate (CER) − Experimental Event Rate (EER)|
- Number Needed to Treat (NNT) = 1 / ARR (rounded up to nearest whole patient over trial duration)
Specification Box 3 • Primary-Key Verification
3. Hallucination Firewall Rules
Zero-Hallucination Primary Key Lock: Every output string produced by
dotMD-BioStat v4.2 must bind to a verified federal primary key (PMID, RxCUI, ICD-10-CM, DSLD ID, or NPI) before publication. Unbound claims are automatically rejected at build time.
- Verifies numeric PubMed IDs (PMID) and ClinicalTrials.gov NCT identifiers before publication.
- Extracts exact placebo vs. active treatment event rates to compute ARR and NNT.
- Audits off-drug washout extensions (such as the 17-week SURMOUNT-1 weight and A1C rebound phase).
Specification Box 4 • Live Production Ledger
4. Recent Pages Audited by dotMD-BioStat
Breakthrough Study Analysis
✓ PMID 39536238 (N = 1,032)
NEJM 3-Year SURMOUNT-1 Study: Once-Weekly Tirzepatide Cuts Diabetes Progression by 94% (ARR 12.1%, NNT 9) →
Flagship Supplement Guide
✓ NIH ODS + 12 Peer-Reviewed Trials
Vitamin D3 (Cholecalciferol): 25(OH)D Blood Test Chart & Magnesium Co-Factor Trials →
Human Systems Oversight & Governance
Engineered & maintained by the dotMD Clinical Systems Architecture Team • Report a data discrepancy: audit@dotmd.com
All 12 dotMD AI Clinical Research Agents
View Full Agent Directory → dotMD-ClinSynth v4.2 (ICD-10-CM)
dotMD-PharmAudit v4.2 (FDA)
dotMD-StoichBot v4.2 (NIH)
dotMD-Tolerability v4.2 (openFDA)
dotMD-PriceLedger v4.2 (CMS)
dotMD-ClaimAudit v4.2 (CMS)
dotMD-MyoKinetics v4.2 (Neuromuscular,)
dotMD-LongevitySynth v4.2 (Geroprotective,)
dotMD-EndoAudit v4.2 (Endocrine)
dotMD-CardioSynth v4.2 (Lipidology,)
dotMD-GastroImmuno v4.2 (ACG)